Positions

Overview

  • My major research interest is in multiple myeloma. I, along with my multiple myeloma colleagues, established an interdisciplinary myeloma clinic in March 2013, which is the first clinic of its kind in Alabama dedicated solely to plasma cell malignancies. I have also represented UAB on the NCCN Multiple Myeloma guidelines panel. My future and ongoing goals include opening and expanding clinical trials for the relapsed/refractory multiple myeloma patient population and to continue to serve the growing multiple myeloma patient population.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myelomaBritish Journal of Haematology.  195:e113-e116. 2021
    2020 Multiple myeloma, version 3.2021 2020
    2020 Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-risk Cytogenetic Factors: A Systematic Review and Meta-analysisJAMA Oncology.  6:1759-1765. 2020
    2019 Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapyLeukemia.  33:2266-2275. 2019
    2019 Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines 2019
    2018 Second primary malignancy after multiple myeloma-population trends and cause-specific mortalityBritish Journal of Haematology.  182:513-520. 2018
    2018 Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple MyelomaBiology of Blood and Marrow Transplantation.  24:1379-1385. 2018
    2018 Multiple Myeloma, version 3.2018: Featured updates to the NCCN guidelines 2018
    2017 Accuracy of Medicare Claim-based Algorithm to Detect Breast, Prostate, or Lung Cancer Bone Metastases.Medical Care.  55:e144-e149. 2017
    2017 Clinical practice guidelines in oncology 2017
    2017 Accuracy of Medicare Claim-based Algorithm to Detect Breast, Prostate, or Lung Cancer Bone MetastasesMedical Care.  55:e144-e149. 2017
    2017 Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United StatesBlood Advances.  1:282-287. 2017
    2016 NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. 2016
    2016 NCCN guidelines® insights multiple myeloma, version 3.2016 featured updates to the NCCN guidelines 2016
    2016 Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical featuresCancer Causes and Control.  27:81-91. 2016
    2015 Multiple myeloma, version 2.2016: Clinical practice guidelines in oncology 2015
    2014 Occult primary, version 3.2014; Featured updates to the NCCN guidelines 2014
    2005 Karyotypic Analysis of Adult Pluripotent Stem Cells 2005

    Research Overview

  • Multiple Myeloma, Plasma cell malignancies
  • Investigator On

  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC
  • BMT CTN 1302- Multicenter Phase II, Double Blinded, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma  awarded by National Marrow Donor Program
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by EMD SERONO
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by MERRIMACK PHARMACEUTICALS, INC.
  • Private Grant  awarded by Novartis Pharma AG
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by Novartis Pharma AG
  • Private Grant  awarded by CYTRX CORPORATION
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by ONYX PHARMACEUTICALS, INC.
  • Private Grant  awarded by BOSTON SCIENTIFIC CORPORATION
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by ELIOS THERAPEUTICS
  • Private Grant  awarded by KARYOPHARM THERAPEUTICS, INC.
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by NEWLINK GENETICS, INC
  • Private Grant  awarded by ELIOS THERAPEUTICS
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by DYNAVAX TECHNOLOGIES CORPORATION
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by Janssen
  • Private Grant  awarded by DYNAVAX TECHNOLOGIES CORPORATION
  • Private Grant  awarded by IDERA PHARMACEUTICALS, INC.
  • Private Grant  awarded by CELGENE INTERNATIONAL II SÀRL
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by MUNDIPHARMA
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by REPLIMUNE INC.
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC.
  • Private Grant  awarded by BRISTOL-MYERS SQUIBB COMPANY
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by TAKEDA DEVELOPMENT CENTER AMERICAS, INC.
  • Private Grant  awarded by NEKTAR THERAPEUTICS, INC.
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC.
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by CHIMERIX, INC.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by ELIOS THERAPEUTICS
  • Prospective Observation of Cardiac Safety with Proteasome Inhibition (PROTECT)  awarded by VANDERBILT UNIVERSITY
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University
  • UAB 1815: Phase 2 Trial of Intensive Chemo-immu,otherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed.Refractory Myeloma In the context of Salvage Autologous Hematopoietic Cell Transplantation  awarded by Memorial Sloan-Kettering Cancer Center
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • Education And Training

  • UAB Hospital, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • Bachelor of Science or Mathematics in Biology, Sewanee/University of the South 2005
  • Doctor of Medicine, Mercer University 2005
  • Full Name

  • Kelly Godby